肾移植患者泌尿生殖系统恶性肿瘤风险
该研究回顾性分析了明尼苏达大学1984至2019年6172例肾移植受者,平均随访10年,比较其泌尿生殖系统恶性肿瘤累积发病率与SEER数据库年龄匹配数据。结果显示肾癌30年累积发病率为4.6%(SEER 1.1%),前列腺癌为8.7%(SEER 11.1%),膀胱癌为1.5%(SEER 1.7%)。结论认为肾移植受者肾癌风险高于非移植人群,前列腺癌风险较低,膀胱癌风险相当。
要点
- 肾移植受者30年肾癌累积发病率为4.6%,高于年龄匹配SEER人群的1.1%。
- 前列腺癌30年累积发病率为8.7%,低于SEER人群的11.1%。
- 膀胱癌30年累积发病率为1.5%,与SEER人群的1.7%相当。
核心结论
- 肾移植受者肾癌发病率高于非移植人群,前列腺癌发病率较低,膀胱癌累积发病率与年龄匹配普通人群相当。
研究设计与样本
- 回顾性队列研究,查询明尼苏达大学1984至2019年所有实体器官移植数据库,纳入6172例肾移植受者,平均随访10年。
主要发现
- 肾癌(移植物及原肾)30年累积发病率为4.6%,前列腺癌为8.7%,膀胱癌为1.5%。
- 年龄匹配SEER数据库30年累积发病率分别为肾癌1.1%、前列腺癌11.1%、膀胱癌1.7%。
- 泌尿生殖系统肿瘤中最常见为肾细胞癌(原肾n=64,移植肾n=11),其次为前列腺癌(n=63)和膀胱癌(n=37)。
关键数值与推荐
- 肾癌30年累积发病率4.6% vs SEER 1.1%;前列腺癌8.7% vs SEER 11.1%;膀胱癌1.5% vs SEER 1.7%。
临床怎么用
- 肾移植受者应关注肾癌风险,尤其是原肾及移植肾;前列腺癌和膀胱癌的筛查可参考普通人群风险。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To better understand the risk of genitourinary malignancies in the renal transplant patient. Currently, no consensus exists regarding screening and intervention, with much of the clinical decision-making based on historical practices established before recent progress in immunosuppression protocols and in genitourinary cancer diagnosis and management. METHODS: A database of all solid organ transplants performed at the University of Minnesota from 1984 to 2019 was queried for renal transplant recipients in whom development of subsequent urologic malignancies (prostate, bladder, renal, penile, and testicular cancer) was found. RESULTS: Among 6172 renal transplant recipients examined, cumulative incidence of all cancers of genitourinary etiology are presented over an average follow-up time of 10 years. Kidney cancer (combined graft and native), prostate cancer, and bladder cancer each demonstrated respective 30-year incidence of 4.6%, 8.7%, and 1.5% from the time of transplant. By comparison, age-matched data from the Surveillance, Epidemiology, and End Results database demonstrated 30-year cumulative incidence of 1.1%, 11.1%, and 1.7% for kidney cancer, prostate cancer, and bladder cancer respectively. The predominant genitourinary cancer was renal cell cancer, both of the native and of the transplanted kidney (native, n = 64; transplanted, n =11), followed by prostate cancer (n = 63), and bladder cancer (n = 37). CONCLUSION: In this closely followed cohort of renal transplant recipients, renal cancer occurs at a higher incidence rate than in the non-transplanted population, while a lower rate of prostate cancer was found, with bladder cancer demonstrating a comparable cumulative incidence between transplant patients and the national age-matched population.
引用
- Jiang S, Regmi S, Jackson S, et al. Risk of Genitourinary Malignancy in the Renal Transplant Patient. Urology. 2020. PMID: 32763322. doi:10.1016/j.urology.2020.06.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。